Posts

Novartis to pay Sironax $125M for brain-delivery platform

on
Novartis exercised an exclusive option to acquire Sironax’s Brain Delivery Module (BDM), a platform intended to move therapies across the blood-brain barrier and into the central nervous system. Sironax is set to receive $125 million at closing. The payment is part of an agreement announced in July 2025 that offered Sironax up to $175 million in upfront and near-term payments. Novartis obtains full global rights to the modality-agnostic platform, which is designed to support brain delivery of monoclonal antibodies, peptides, proteins and potentially gene therapies. Sironax retains rights to develop and commercialize selected therapeutic assets using the technology, while planning to use the proceeds to advance its own pipeline. The deal reflects Novartis’s push into neuroscience drug delivery, where safely and efficiently crossing the blood-brain barrier remains a major obstacle for treatments of diseases such as Alzheimer’s, Parkinson’s, Huntington’s and ALS. Sources: Nova...

Vera’s Strong Trutakna Data Heat Up the IgA Nephropathy Drug Race

on

Axoltis touts secondary ALS trial findings after primary endpoint miss

on

Sling raises $123M to push oral thyroid-eye-disease drug into Phase 3

on

Novartis drops VHB937 ALS program after Phase 2 failure

on

BMS and Ono sue Amgen as FDA weighs Opdivo biosimilar

on

O’Day says Gilead’s cancer and inflammation strategy has reached ‘critical mass’

on

RegCell raises $66 million to advance T-cell reprogramming

on

Contineum’s J&J-partnered M1 antagonist flunks another trial

on

GE HealthCare expands CareIntellect with AI for hospital operations

on

Contineum–J&J depression drug misses Phase 2 trial goal

on

FDA Launches Expedited IND Pilot After Incorporating Stakeholder Feedback

on

Microstructure Imaging Wins FDA Clearance for MICSI-PET

on